Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Wave Neuroscience tells Senate committee ETMS pilots show large symptom reductions for PTSD and substance use
Summary
Wave Neuroscience and local providers told the Senate Armed Services, Veterans Affairs and Public Safety Committee that EEG‑guided transcranial magnetic stimulation (ETMS) produced substantial symptom reductions in pilot patients with PTSD and substance use disorder, and requested state support to expand access.
Dr. Juan of Wave Neuroscience told the Senate Armed Services, Veterans Affairs and Public Safety Committee that EEG‑guided transcranial magnetic stimulation (ETMS) has produced striking clinical signals in pilots for post‑traumatic stress disorder and substance use disorders. He said the company received an FDA Breakthrough Device designation in November 2024 and presented program figures and pilot outcomes for committee members.
The company representative said the ETMS workflow combines an EEG brain map with targeted transcranial magnetic stimulation and reported program‑level outcomes of roughly 835 patients treated, more than 4,000 clinical scales collected and over 2,600 EEGs performed. "Our ETMS data show a 63 percent improvement in PCL‑5 scores," Dr. Juan said, referring to a commonly used PTSD…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
